Lantus What to Expect: Week-by-Week First Month on Insulin Glargine

Why the First Month Is the Most Important Period

The first four weeks on insulin glargine set the trajectory for long-term glycemic control. This is when your provider identifies your correct maintenance dose, when your body adapts to exogenous basal insulin, and when the risk of dosing errors is highest. Getting the titration right during weeks 1 through 4 can cut the time to target A1C by months.

What Insulin Glargine Actually Does in Your Body

Lantus is a long-acting basal insulin analog. After subcutaneous injection, the acidic formulation (pH 4) precipitates in the neutral tissue environment, forming micro-crystals that dissolve slowly. The result is a flat, peakless absorption profile lasting 20 to 24 hours for U-100 glargine and up to 36 hours for U-300 (Toujeo). That flat profile is the whole point. Unlike NPH insulin, which peaks at 4 to 8 hours and causes nocturnal hypoglycemia at much higher rates, glargine suppresses hepatic glucose output continuously without a spike. A 2000 New England Journal of Medicine study comparing glargine with NPH in type 1 diabetes (N=534) found that symptomatic nocturnal hypoglycemia was 42% less frequent with glargine at 28 weeks.

Why Timing and Injection Technique Matter From Day One

Glargine should be injected at the same time each day. Rotation through abdomen, thigh, and upper arm sites is required to prevent lipohypertrophy, a subcutaneous fatty deposit that slows and erratizes absorption. The FDA-approved prescribing information for Lantus specifies that the drug must not be diluted or mixed with any other insulin or solution. The FDA label for Lantus is available on FDA.gov.

Week 1: Getting the Baseline Right

The primary job of week 1 is establishing a reliable fasting glucose measurement, not achieving target. Your provider will almost certainly start you at 10 units once daily or at 0.1 to 0.2 units/kg body weight, per the 2024 American Diabetes Association Standards of Care.

What Your Numbers Will Look Like

Expect your fasting glucose to drop, but probably not to target yet. A typical type 2 patient starting at 10 units with a fasting glucose of 220 mg/dL might see readings in the 170 to 190 mg/dL range by day 5 to 7. That is progress. The dose is still sub-therapeutic for many patients. Do not increase the dose on your own during week 1 without contacting your provider.

The Injection Itself

The SoloSTAR pen delivers glargine through a fine-gauge needle (typically 31G x 4 mm or 32G x 4 mm). Most patients describe the injection as a mild sting. The slight burning sensation that some patients notice is due to the acidic pH of the formulation, not a sign of incorrect technique. If you see a droplet of solution at the injection site, you may not have completed the full dose. The prescribing information recommends performing a safety test before each dose to confirm needle flow.

Side Effects to Watch in Week 1

Hypoglycemia is the side effect that matters most. At a starting dose of 10 units, true hypoglycemia (<70 mg/dL) in week 1 is uncommon but not impossible, particularly if you are also taking a sulfonylurea (like glipizide or glimepiride). The ADA 2024 Standards of Care recommend considering a sulfonylurea dose reduction when basal insulin is initiated, citing additive hypoglycemia risk.

Mild injection-site redness or swelling affects roughly 1 in 10 new users and typically resolves within a week.

Week 2: The First Titration Step

Week 2 is when most protocols call for the first dose adjustment. The most widely used self-titration algorithm, the "2-2-2" or "treat-to-target" approach, increases glargine by 2 units every 3 days when the fasting glucose average exceeds 130 mg/dL.

The Treat-to-Target Trial and What It Proved

The Treat-to-Target Trial (N=756, type 2 diabetes) published in Diabetes Care demonstrated that patients titrating glargine according to a structured algorithm reached an A1C of 6.96% at 24 weeks, versus 6.97% with NPH, with significantly less nocturnal hypoglycemia (fewer than one event per patient-year with glargine vs. 1.66 events with NPH). The Treat-to-Target Trial is indexed at PubMed.

That trial validated the principle that self-titration using fasting glucose is safe and effective. Your provider may use a slightly different increment (1, 2, or 4 units every 3 days) depending on your starting glucose and body weight.

How to Log Your Fasting Glucose Correctly

Check fasting glucose on waking, before any food or drink other than water, at least 3 days before your week-2 check-in call. Use the average of those 3 readings to guide titration, not a single outlier. One elevated reading after a late dinner does not justify a large dose increase. One low reading may indicate you need to hold the current dose.

Hypoglycemia Risk Climbs Slightly in Week 2

As the dose increases, so does hypoglycemia risk. Know the symptoms: shakiness, sweating, heart racing, confusion. The "15-15 rule" applies: 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz orange juice), wait 15 minutes, recheck. The ADA position statement on hypoglycemia management recommends this approach.

Week 3: Approaching the Therapeutic Dose

By week 3, many patients are in the 16 to 24 unit range. Fasting glucose readings begin clustering below 150 mg/dL for most patients who are titrating consistently. Some patients with significant insulin resistance may need 40 to 60 units or more. That is not a failure. Body weight and insulin sensitivity drive the final dose.

The Role of the ORIGIN Trial

The ORIGIN trial (N=12,537, NEJM 2012, median follow-up 6.2 years) tested whether early basal insulin in people with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) reduced cardiovascular events. The answer was neutral: no increase and no decrease in major adverse cardiovascular events (MACE) compared with standard care. The ORIGIN trial is available in full at NEJM.

What ORIGIN also showed is that glargine titrated to a fasting glucose target of <95 mg/dL was achievable in a large diverse population, and that the drug was safe over a median 6.2-year period. The annualized rate of severe hypoglycemia in the glargine arm was 1.00 per 100 patient-years, compared to 0.31 per 100 patient-years in the standard-care arm. That means risk is real but manageable with proper titration.

What Happens to Your A1C at Week 3

A1C does not change meaningfully in 3 weeks. The glycated hemoglobin molecule reflects the average glucose over 2 to 3 months. What you will see at week 3 is a meaningful drop in fasting glucose and, often, an improvement in daytime energy as glucose excursions flatten out. Patients frequently report sleeping better and feeling less fatigued. That is the fasting glucose control beginning to extend overnight glucose suppression.

Medication Interactions to Reassess at Week 3

If you are on a corticosteroid, glucocorticoid-containing inhalers, or antipsychotics that raise glucose (olanzapine, quetiapine), your glargine dose requirements will be substantially higher. Tell your provider about any new or changed medications at every titration check-in. The FDA label for Lantus lists dozens of drug interactions affecting insulin requirements.

Week 4: Consolidating the Dose and Setting Goals

Week 4 is usually the first checkpoint where your provider can assess whether the starting strategy worked. If your fasting glucose average is now 80 to 130 mg/dL on 3 consecutive days, titration is complete for the near term. If post-meal glucose spikes remain high despite controlled fasting glucose, a mealtime insulin or a GLP-1 receptor agonist may be added.

What the Average Patient Achieves in 4 Weeks

The following 4-week outcome framework is drawn from published titration trial data and the HealthRX clinical team's analysis of the Treat-to-Target, ORIGIN, and AT.LANTUS trials. It is intended as a general orientation, not a guarantee for any individual patient.

| Week | Typical Fasting Glucose Range | Expected Dose (Type 2, 80 kg) | Key Focus | |------|------------------------------|-------------------------------|-----------| | 1 | 160 to 220 mg/dL | 10 to 12 units | Injection technique, baseline logging | | 2 | 140 to 180 mg/dL | 12 to 18 units | First titration, hypoglycemia awareness | | 3 | 120 to 160 mg/dL | 18 to 28 units | Continued titration, reassess co-meds | | 4 | 90 to 140 mg/dL | 22 to 36 units | Confirm target, assess post-meal spikes |

These ranges represent medians. Individual variation is wide. Patients with very high insulin resistance (BMI >40, significant steroid use) may need 60 to 100 units or more.

The AT.LANTUS Trial and Flexible Dosing

The AT.LANTUS trial (N=4,961, type 2 diabetes) compared patient-led versus physician-led titration of glargine. Both groups achieved similar A1C reductions (approximately 1.2% from baseline at 24 weeks), but patient-led titration reached target fasting glucose faster and with similar hypoglycemia rates. AT.LANTUS is indexed at PubMed. This evidence supports the practice of teaching patients to self-titrate from day one, within the guardrails of a specific protocol.

Weight Gain: What to Expect and How to Minimize It

In ORIGIN, patients in the glargine arm gained an average of 1.6 kg over 6 months, compared to a loss of 0.5 kg in the standard-care arm. Weight gain with basal insulin is real and results from two mechanisms: reduced glucosuria (less glucose lost in urine as control improves) and the anabolic effect of insulin itself. Pairing glargine with a GLP-1 receptor agonist (semaglutide, liraglutide) substantially attenuates or reverses this weight gain, as shown by the DUAL trials of insulin degludec/liraglutide combination and comparable combination data.

Injection Site Rotation and Lipohypertrophy Prevention

Lipohypertrophy affects up to 30% of insulin users in cross-sectional studies and is a direct cause of erratic absorption. A lumpy injection site can delay or blunt insulin action, causing unexplained glucose variability. A 2014 study in Diabetes Technology and Therapeutics (N=388 insulin users) found that 28.7% had detectable lipohypertrophy by ultrasound, and those patients had significantly higher A1C and more hypoglycemia.

Practical Rotation Protocol

Divide each injection zone (abdomen, outer thigh, upper arm, upper buttock) into a grid. Move at least 1 cm (about one finger-width) from the previous injection point. Use the same zone at the same time each day (e.g., always the abdomen for the evening dose) to reduce pharmacokinetic variability from site-to-site absorption differences. Change needles with every injection. Reusing needles blunts the tip and increases tissue trauma.

Hypoglycemia: Recognizing, Treating, and Preventing

Nocturnal hypoglycemia is the hypoglycemia type most associated with basal insulin. It typically occurs between 2 a.m. And 4 a.m. And may present as night sweats, vivid dreams, morning headache, or rebound hyperglycemia (the Somogyi effect, though the clinical significance of Somogyi is debated).

When to Check at 2 a.m.

If you wake with a headache or find your fasting glucose unexpectedly above 180 mg/dL after a period of lower readings, check blood glucose at 2 to 3 a.m. For 2 to 3 nights. A reading below 70 mg/dL at that time confirms nocturnal hypoglycemia, and the dose should be reduced by 2 to 4 units at the next contact with your provider.

Hypoglycemia Unawareness

Patients who have had diabetes for more than 10 years, those with autonomic neuropathy, and those on beta-blockers may have impaired hypoglycemia awareness (HUA). HUA means the normal adrenergic warning symptoms (tremor, sweating, palpitations) do not appear until blood glucose falls well below 54 mg/dL. The ADA defines Level 2 hypoglycemia as blood glucose <54 mg/dL (3.0 mmol/L) and states that this level requires immediate treatment regardless of symptoms. Patients with HUA should consider continuous glucose monitoring (CGM) from the first week.

Special Populations: Adjustments in the First Month

Older Adults (Age 65 and Above)

The ADA and AACE both recommend a more conservative fasting glucose target of 80 to 180 mg/dL in older adults with multiple comorbidities or limited life expectancy, to reduce hypoglycemia-related falls and cardiac events. Start at 6 to 8 units and titrate by 1 unit every 3 days. AACE/ACE Comprehensive Diabetes Management Algorithm 2020 is available through the AACE.

Kidney Disease (eGFR <60 mL/min)

Insulin clearance decreases as kidney function declines. Patients with CKD stage 3b or worse (eGFR <45) may require 20 to 30% lower doses and more frequent monitoring. Hypoglycemia risk rises substantially in dialysis patients. The dose should be re-evaluated at every eGFR change.

Type 1 Diabetes

In type 1 diabetes, glargine covers only the basal component. Patients also need rapid-acting insulin (lispro, aspart, or glulisine) at meals. The typical basal dose in type 1 is 40 to 50% of total daily insulin. Starting without a mealtime component in type 1 diabetes will not achieve target glucose and is not recommended.

Storing Lantus Correctly From Day One

Unopened Lantus vials and SoloSTAR pens must be refrigerated at 2 to 8°C (36 to 46°F). Once in use, U-100 SoloSTAR pens can be stored at room temperature (below 30°C / 86°F) for up to 28 days. U-300 (Toujeo) in-use pens last up to 42 days unrefrigerated. Never freeze glargine. Frozen insulin is denatured and ineffective. Never leave it in a hot car. Direct sunlight degrades the formulation within hours.

Visually inspect before every injection. Glargine should be clear and colorless. Any cloudiness, discoloration, or visible particles means the pen or vial should be discarded. The FDA label specifies these storage and inspection requirements.

When to Call Your Provider Before the 4-Week Check-In

Do not wait for the scheduled check-in if any of the following occur.

• Blood glucose falls below 54 mg/dL at any time.
• You lose consciousness or require assistance to treat a hypoglycemic episode.
• Fasting glucose exceeds 300 mg/dL on two consecutive mornings despite dose increases.
• You develop a fever, infection, or start a new corticosteroid prescription. Illness and glucocorticoids raise insulin requirements rapidly and unpredictably.
• Injection sites show signs of infection (warmth, redness, pus) rather than the typical transient reaction.
• You are pregnant or planning to become pregnant. Pregnancy substantially changes insulin requirements and requires specialist oversight.

The Endocrine Society's clinical practice guideline on management of diabetes in hospitalized patients notes that hyperglycemia and hypoglycemia both increase morbidity, and that frequent glucose monitoring with prompt dose adjustment is the standard of care. The Endocrine Society guideline is available via their journal.

Glossary of Key Terms

Basal insulin. Background insulin that suppresses overnight and between-meal hepatic glucose production.

Lipohypertrophy. Fatty lump at an injection site caused by repeated injections in the same spot. Slows and distorts insulin absorption.

Fasting plasma glucose (FPG). Blood glucose measured after at least 8 hours with no caloric intake. The primary titration target for basal insulin.

Titration. Systematic, incremental dose adjustment toward a predefined glucose target.

Hypoglycemia unawareness (HUA). Absence of the usual warning symptoms before blood glucose drops to dangerous levels.